Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2013
05/21/2013CA2349203C Dispersible phospholipid stabilized microparticles
05/21/2013CA2305385C Human toll homologues
05/21/2013CA2294865C Immunogenic lhrh compositions and methods relating thereto
05/21/2013CA2279329C Protein fragment complementation assays to detect biomolecular interactions
05/16/2013WO2013071262A1 Calcimimetics and methods for their use
05/16/2013WO2013071231A1 Channelrhodopsins for optical control of cells
05/16/2013WO2013071154A1 Cyclin a1-targeted t-cell immunotherapy for cancer
05/16/2013WO2013071142A1 Biomarkers of response to proteasome inhibitors
05/16/2013WO2013071049A1 Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
05/16/2013WO2013071030A1 Provasopressin antagonists and uses thereof
05/16/2013WO2013070808A1 Peptide-based compounds as inhibitors of neurotransmitter secretion
05/16/2013WO2013070741A1 Methods and materials for regulating natriuretic polypeptide function
05/16/2013WO2013070734A1 Methods of cardiac repair
05/16/2013WO2013070603A1 Compositions and methods for treatment of kidney diseases
05/16/2013WO2013070529A1 Compositions and methods for inhibiting the interaction between cftr and cal
05/16/2013WO2013070362A1 Compositions and methods for immune tolerance induction
05/16/2013WO2013070048A1 Composition for preventing or treating ischaemic heart disease comprising, as an active ingredient, age-albumin synthesis or secretion inhibitor for mononuclear phagocyte system cells
05/16/2013WO2013070011A1 Pharmaceutical composition for the prevention or treatment of neurological diseases comprising an ampa receptor endocytosis inhibitor
05/16/2013WO2013070010A1 Novel composition for gene delivery
05/16/2013WO2013068964A1 Pharmaceutical composition for the prevention and the treatment of degenerative skin disorders especially caused by ionizing radiations
05/16/2013WO2013068776A1 Combination of active ingredients for the treatment of acute kidney injury
05/16/2013WO2013068701A1 Urotensin-ii for use in the treatment and/or prevention of diseases involving gastric motility
05/16/2013WO2013068590A1 Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization
05/16/2013WO2013068538A1 Process of purification of teicoplanin
05/16/2013WO2013068517A1 Process of purification of teicoplanin
05/16/2013WO2013068504A1 Apotransferrin for the treatment of brain stroke
05/16/2013WO2013068476A1 Neurotoxins exhibiting shortened biological activity
05/16/2013WO2013067770A1 Compositions and methods for treating traumatic brain injury
05/16/2013WO2013067750A1 Polyclonal antibody immunologic mass spectrometry kit of liver cancer marker
05/16/2013WO2013067639A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
05/16/2013WO2013044044A3 Methods of treating fatty liver disease with helminth-derived glycan-containing compounds
05/16/2013WO2013040504A3 Srpx for treatment of cancer
05/16/2013WO2013020108A3 Bile acid recycling inhibitors for treatment of pancreatitis
05/16/2013WO2013015611A9 Composition for preventing damage to chondrocytes and regenerating same, including yeast hydrolysate as an active ingredient
05/16/2013WO2012174534A3 Method of treating or ameliorating metabolic disorders using clec-2
05/16/2013WO2012068515A3 Compositions and methods for hair growth
05/16/2013US20130125259 Rna interference mediating small rna molecules
05/16/2013US20130123920 Device for tendon and ligament treatment
05/16/2013US20130123201 Modulation of cytokine-induced chronic inflammatory responses
05/16/2013US20130123200 Mammalian cell surface antigens; related reagents
05/16/2013US20130123198 Modulation of scleraxis using a dominant negative scleraxis mutant with a basic dna-binding domain deletion
05/16/2013US20130123195 Sustained action formulation of cyclosporin form 2
05/16/2013US20130123194 Autoclavable suspensions of cyclosporin a form 2
05/16/2013US20130123191 Methods of inhibiting photoreceptor apoptosis
05/16/2013US20130123190 Methods for Treating Combined Radiation and Thermal Injury
05/16/2013US20130123189 Determination of single nucleotide polymorphisms useful to predict response for glatiramer acetate
05/16/2013US20130123186 Neuroprotection using nap-like and sal-like peptide mimetics
05/16/2013US20130123185 Methods of treating and diagnosing acute chest syndrome
05/16/2013US20130123184 Methods for increasing levels of human fetal hemoglobin
05/16/2013US20130123183 Anti-tumor Fibrillar Human Serum Albumin Methods and Compositions
05/16/2013US20130123177 Method of treating brain injury
05/16/2013US20130123174 Neuritogenic peptides
05/16/2013US20130123173 Creation of oxidation-resistant hdl mimetic peptides
05/16/2013US20130123170 Growth Hormone Releasing Peptides
05/16/2013US20130123168 Humanin and humanin-analogues for the management of atherosclerosis
05/16/2013US20130123167 Drug inhibiting the progression of atherosclerosis, preventive drug, blood cholesterol-lowering drug, functional food, and specific health food
05/16/2013US20130123122 Secreted proteins and uses thereof
05/16/2013US20130122086 Method for treating celiac disease
05/16/2013US20130122083 Dna vaccines encoding heat shock proteins
05/16/2013US20130122082 Methods And Compositions For The Treatment And Prevention Of Aging-Associated Conditions
05/16/2013US20130122076 Transdermal Patch Having Ultrasound Transducer for Administering Thrombolytic Reagents to Patients Having a Protein Misfolding Disease
05/16/2013US20130122075 Encapsulated transfer factor compositions and methods of use
05/16/2013US20130122066 Drug delivery devices and growth factor formulations for accelerated wound healing
05/16/2013US20130122059 Suspensions of cyclosporin a form 2
05/16/2013US20130122053 Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
05/16/2013US20130122050 Compositions and methods for treating diabetes using lisofylline analogs and islet neogenesis associated peptide
05/16/2013US20130122046 Regulatory factor of foxp3 and regulatory t cells and use thereof
05/16/2013US20130122031 Hmgb1-derived peptides enhance immune response to antigens
05/16/2013US20130122018 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/16/2013US20130122017 Osteoprotegerin in Neuroprotection
05/16/2013US20130122013 Anti-ferroportin 1 monoclonal antibodies and uses thereof
05/16/2013US20130122011 Multiple-variable dose regimen for treating TNFa-related disorders
05/16/2013US20130121986 Nitrogenated derivatives of pancratistatin
05/16/2013US20130121985 Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
05/16/2013US20130121984 Biomarkers for sanfilippo syndrome and uses thereof
05/16/2013US20130121982 Antidote to the bite of venomous snakes
05/16/2013US20130121974 Methods of making enhanced, autologous fat grafts
05/16/2013US20130121965 Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
05/16/2013US20130121964 Pharmacogenomic and Response-Guided Treatment of Infectious Disease Using Yeast-Based Immunotherapy
05/16/2013US20130121956 Composition for Enhancing Bone Formation
05/16/2013CA2855358A1 Cyclin a1-targeted t-cell immunotherapy for cancer
05/16/2013CA2855356A1 Biomarkers of response to proteasome inhibitors
05/16/2013CA2855173A1 Neurotoxins exhibiting shortened biological activity
05/16/2013CA2855155A1 Treatment of hematologic malignancies with an anti-cxcr4 antibody
05/16/2013CA2854949A1 Apotransferrin for the treatment of brain stroke
05/16/2013CA2854911A1 Calcimimetics and methods for their use
05/16/2013CA2854563A1 Provasopressin antagonists and uses thereof
05/16/2013CA2854467A1 Antagonists for abnormal vasopressin v2 receptor and uses thereof
05/16/2013CA2854372A1 Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
05/16/2013CA2840900A1 Composition for prevention or treatment of ischemic cardiac disease,comprising inhibitor against age-albumin synthesis or release of mononuclearphagocyte system cells as active ingredient
05/15/2013EP2592155A2 EGFR mutations
05/15/2013EP2592090A1 Process of purification of teicoplanin
05/15/2013EP2592089A1 Process of purification of teicoplanin
05/15/2013EP2592088A1 Cyclic peptide compound or pharmacologically acceptable salt thereof and method for producing same
05/15/2013EP2591806A1 Medicinal composition
05/15/2013EP2591797A1 Regulatory factor of foxp3 and regulatory t cells and use thereof
05/15/2013EP2591796A1 Combination medicament comprising IL-12 and an anti-CTLA-4 ligand for tumor therapy
05/15/2013EP2591795A1 RNA targeting compounds and methods for making and using same
05/15/2013EP2591794A1 MicroRNA expressions abnormalities in pancreatic endocrine and acinar tumors
05/15/2013EP2591793A2 Treatment of autoimmune disease